Merck & Co., Inc. (MRK) Licensing HIV Experimental Drugs  
8/24/2012 7:09:39 AM

Drugmaker Merck & Co., a pioneer in AIDS research, is licensing two experimental HIV drugs from other companies and advancing one of its own into mid-stage patient testing. Merck, based in Whitehouse Station, Hunterdon County, said Tuesday that it’s signed one deal with Chimerix Inc. for a compound called CMX157, a pill in the HIV drug class called nucleoside reverse transcriptase inhibitors that’s now in early patient testing. Merck will take over development of the drug and get an exclusive worldwide license to market it from Chimerix, based in Research Triangle Park, N.C.